Pharmaceutical disputes continued to generate the largest share of IMRs at 30.8%, with dermatologicals making up 25.9% of pharmaceutical disputes.
Pharmaceutical disputes continued to generate the largest share of IMRs at 30.8%, with dermatologicals making up 25.9% of pharmaceutical disputes.
GLP-1s represented 0.02% of total medical spend in workers’ comp in 2025 – or $1.9 million out of $9.3 billion.
Pharmacy costs decreased 15%, but overall medical costs rose 4%.
A small number of high-cost meloxicam capsule prescriptions sharply increased the drug’s average payment from $9 in 2020 to $92 in 2025.
Drugs remained approximately 10% of medical costs, with physician-dispensed drugs accounting for 5% of total drug payments.
Cost growth of services not subject to fee schedule caps has accelerated in recent years, driven largely by higher utilization.
Many states experienced higher medical payments, driven by higher prices for professional services and evolving trends in prescription drug utilization.
A 100% tariff is expected to take place August 1, 2028 for generic drugs imported into the U.S., followed by a 200% tariff in August 2029.
The Committee is focused on high-cost and high-utilization medications, including GLP-1s, PPIs, anticonvulsants, topical agents, and biologics.
While migraine drugs make up less than 1% of prescriptions, they now make up 7.5% of drug spend, primarily driven by CGRP drugs.
Pharmaceutical requests represented 30.6% of all treatment requests submitted for IMR, a modest decline from 32.7% in 2024.
Dermatological agents remained a significant cost driver, in part due to physician dispensing and delivery pharmacies, which accounted for a significant number of high-cost transactions.
Prescription drug list prices increased 23% in the last year, far outpacing inflation.
While opioid utilization has decreased, overall spend on pain management has increased, in part due to the use of high-cost topical medications.
While this drug class represents less than 1% of prescriptions, it accounted for 3.4% of drug spend.